Pricing Log in Create free account
Friday 6 November 2026 Export UTHR’s income statement to Excel — free account

United Therapeutics Corporation

UTHR Healthcare Drug Manufacturers Specialty & Generic

United Therapeutics Corporation’s revenue for fiscal 2025 (year ended December 2025) was $3.2 billion, up 10.6% from fiscal 2024.

Revenue
+4.13%
EPS
−21.7%
Free cash flow
−63.7%

Quarter to September 2026, against a year earlier

562.81 2.91 −0.51%
Market cap
$24.3B
P/E
19.7×
Fwd P/E
22.5×
Dividend yield
—
F-score
8/9
Altman Z
19.55
Beneish M
−2.26
Dividend safety
n/a
Overview Business Profile Earnings & Analysis
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios
Segments Valuation Filings

United Therapeutics Corporation 8-K filed Oct 22, 2026

Period ended Oct 21, 2026 · Filed · accepted 7:00 AM ET · Document on sec.gov · Filing index

8.01 Other events; 9.01 Financial statements and exhibits

Nothing in this filing raised a red flag, and we have no summary of it. The items it reports are listed above; the document itself is on sec.gov.

Read the filing on sec.gov